The Medicines Patent Pool has signed agreements with nine patent holders for thirteen HIV antiretrovirals, one HIV technology platform, a tuberculosis treatment and three hepatitis C direct-acting antivirals. 23 generic manufacturers and product developers have now signed MPP sublicensing agreements.

Overview of all licensing and sublicensing agreements

Generic competition is making a difference in fostering lower prices and improving treatment coverage. Generic partners have distributed 26 million patient-years of HIV and hepatitis C products, saving international procurers USD1.23 billion (Jan. 2012-June 2019).


Last update of the table: October 2019 (data as of June 2019)
[WHO-PQ] Prequalification from the World Health Organization | [USFDA] U.S. Food and Drug Administration | [ERP] Expert Review Panel led by the World Health Organization

This website uses cookies to ensure you get the best experience on our website. Learn More